Welcome to the CaPTAA project website

This website aims to take a proactive role by informing citizens, healths professionals and scientists about CaPTAA research activities in the field of cardiac research using the progenitors as a mean towards therapy.

CaPTAA stands for Cardiac Progenitors TransAtlantic Alliance. Its a network between European and American scientists founded by the Leducq fondation

heart damage by an infarctus an normal heart

Cardiac cell replacement therapy has emerged as a potentially new means of regenerating irreversibly damaged areas following myocardial infarction. This novel approach has major implications for cardiomyopathy and resulting heart failure. To be successful, the implanted cells should meet two major criteria:

1) to be able to engraft into the recipient myocardium for a prolonged time period; and 2) to form electromechanical connections with host cardiomyocytes to allow synchronous contraction and long term improvement in left ventricular function.

Our five-year programme is to establish an American-European network of international excellence that will focus on the scientific, diagnostic, prognostic, and therapeutic value of cardioblasts for autologous cell therapy in the setting of heart failure, arrhythmogenesis, cardiac disorders of neuromuscular diseases and congenital heart disease.